The present invention relates to a composition which comprises an electron-transporting host and a hole-transporting host, to the use thereof in electronic devices and to electronic devices containing this composition. The electron-transporting host is particularly preferably selected from the class of the triazine-dibenzofuran-carbazole systems or the class of the triazine-dibenzothiophene-carbazole systems. The hole-transporting host is preferably selected from the class of the biscarbazoles.

Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, arid methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.

Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, arid methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.

A luminescent compound has a structure represented by a general formula (1),

##STR00001##

wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.

A luminescent compound has a structure represented by a general formula (1),

##STR00001##

wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.

Provided is a compound having higher fluorescence quantum yield and higher optical stability than a conventional FLAP and a polymer compound containing the compound. ##STR00001## A: seven or eight-membered ring structure, Y.sup.1, Y.sup.2, Y.sup.3: halogen atom or the like, a1: number of Y.sup.1, a2: number of Y.sup.2, B: number of Y.sup.3, 0≤m and n≤3: when 1≤m≤3, Y.sup.1 may be substituted with a structure portion defined by m, when 1≤n≤3, Y.sup.2 may be substituted with a structure portion defined by n, and B.sup.1, B.sup.2: Formulas (2-1) to (2-3). ##STR00002## C.sup.1, C.sup.2, C.sup.3: structure containing a cyclic hydrocarbon compound, D.sup.1, D.sup.2, D.sup.3: substructure that inhibits aggregation, E.sup.1, E.sup.2, E.sup.3: polymerizable substructure, Z.sup.1: hydrogen atom or the like, c: number of substituent groups Z.sup.1, Z.sup.2, Z.sup.3: hydrogen atom or the like, and may form a ring with C.sup.2.

Provided is a compound having higher fluorescence quantum yield and higher optical stability than a conventional FLAP and a polymer compound containing the compound. ##STR00001## A: seven or eight-membered ring structure, Y.sup.1, Y.sup.2, Y.sup.3: halogen atom or the like, a1: number of Y.sup.1, a2: number of Y.sup.2, B: number of Y.sup.3, 0≤m and n≤3: when 1≤m≤3, Y.sup.1 may be substituted with a structure portion defined by m, when 1≤n≤3, Y.sup.2 may be substituted with a structure portion defined by n, and B.sup.1, B.sup.2: Formulas (2-1) to (2-3). ##STR00002## C.sup.1, C.sup.2, C.sup.3: structure containing a cyclic hydrocarbon compound, D.sup.1, D.sup.2, D.sup.3: substructure that inhibits aggregation, E.sup.1, E.sup.2, E.sup.3: polymerizable substructure, Z.sup.1: hydrogen atom or the like, c: number of substituent groups Z.sup.1, Z.sup.2, Z.sup.3: hydrogen atom or the like, and may form a ring with C.sup.2.

The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.

The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.

The present disclosure relates to a novel compound for photodynamic therapy of cancer, a composition including the same, and a method for photodynamic therapy of cancer, and more specifically, a novel photosensitizer compound based on Nplmidazole having a C═S functional group introduced, a composition and sensor including the same and a method for photodynamic therapy using the same.